MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH

Their core work

Mediagnost is a German SME that develops and manufactures diagnostic kits and immunoassays, with particular strength in biomarker-based diagnostics. In H2020, they contributed diagnostic tool development expertise to projects targeting sepsis prognosis and non-alcoholic fatty liver disease (NAFLD). Their role bridges the gap between biomarker discovery in academic research and commercially viable diagnostic products, making them a natural industry partner for translational biomedical projects.

What they specialise in

How they've shifted over time

Mediagnost's H2020 journey shows a clear thematic shift. Their earliest project (Vaprosep, 2015) focused on sepsis biomarker validation, where they acted as coordinator with SME Instrument Phase 1 funding — a classic market feasibility study for a diagnostic product. By 2017, they pivoted entirely toward NAFLD, joining two related MSCA projects (Foie Gras and mtFOIE GRAS) that explore metabolic and mitochondrial dimensions of liver disease. This suggests a strategic move from acute-care diagnostics toward the larger chronic metabolic disease market.

Mediagnost is moving toward non-invasive diagnostic tools for chronic metabolic diseases, particularly liver conditions — a growing clinical need with significant commercial potential.

How they like to work

Mediagnost operates flexibly across roles: they coordinated their own SME Instrument feasibility study (Vaprosep), served as a full partner in Foie Gras, and joined mtFOIE GRAS as a third party — suggesting they adapt their involvement level to what each project needs. With 16 unique partners across 10 countries from just 3 projects, they are comfortable in broad international consortia. Their participation in MSCA mobility schemes (RISE, ITN) indicates openness to hosting researchers and engaging in knowledge exchange, not just delivering products.

Despite only three projects, Mediagnost has built a surprisingly broad network of 16 partners across 10 countries, driven by the large MSCA consortia addressing NAFLD. Their connections span academic and clinical institutions focused on metabolic research across Europe.

What sets them apart

Mediagnost brings something rare to academic consortia: they are an actual diagnostic product manufacturer, not a university lab or consultancy. This means they can take biomarker discoveries from research projects and translate them into commercial diagnostic kits — a concrete path to market that strengthens any consortium's exploitation plan. For researchers working on disease biomarkers who need an industry partner with real manufacturing capability, Mediagnost fills a very specific niche.

Highlights from their portfolio

• Vaprosep
  Their only coordinated project — an SME Instrument Phase 1 studying the commercial viability of progranulin as a sepsis diagnostic biomarker.
• mtFOIE GRAS
  Five-year MSCA-RISE project on mitochondrial profiling in NAFLD, combining staff mobility with diagnostic tool development across a large international consortium.